Please use this identifier to cite or link to this item:
Title: Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes : an approach for improved oral pharmacokinetics of Sorafenib
Authors: Muhammad Adeeb Khan
Shaukat Ali
Venkatraman, Subbu S.
Muhammad Farhan Sohail
Muhammad Ovais
Abida Raza
Keywords: Engineering::Materials
Issue Date: 2018
Source: Muhammad Adeeb Khan, Shaukat Ali, Venkatraman, S. S., Muhammad Farhan Sohail, Muhammad Ovais, Abida Raza. (2018). Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes : an approach for improved oral pharmacokinetics of Sorafenib. International Journal of Pharmaceutics, 542(1-2), 196-204. doi:10.1016/j.ijpharm.2018.03.023
Journal: International Journal of Pharmaceutics
Abstract: Sorafenib (SFN), a hydrophobic anticancer drug, has several limitations predominantly poor aqueous solubility and hepatic first-pass effect, limiting its oral delivery that results into several other complications. Present study aims to develop Sorafenib loaded polymersomes using poly butadiene block poly ethylene oxide (PB-b-PEO), an amphiphilic co-block polymer. Prior to drug loading, critical aggregate concentration (CAC) of polymer was calculated for stable formulation synthesis. The developed SFN loaded PB-b-PEO polymersomes (SFN-PB-b-PEO, test formulation) characterized by DLS and cryo-TEM showed particle size 282 nm, polydispersity (PDI) of less than 0.29 and membrane thickness of about 20 nm. SFN-PB-b-PEO polymersomes demonstrated encapsulation efficiency of 71% and showed sustained drug release up to 144 h. Formulation remained stable for 3 months in suspension form. In vitro cytotoxicity against HepG2 cells showed 1.7 folds improved toxicity compared to SFN suspension. In addition, oral administration of SFN-PB-b-PEO polymersomes in BALB/c mice showed increased Cmax and AUC0-96 by 1.7 and 2.77-fold respectively (p < 0.05) compared to those of SFN suspension (reference formulation). Findings suggest that the SFN-PB-b-PEO polymersomes can be a potential candidate for oral delivery of SFN.
ISSN: 0378-5173
DOI: 10.1016/j.ijpharm.2018.03.023
Rights: © 2018 Elsevier B.V. All rights reserved.
Fulltext Permission: none
Fulltext Availability: No Fulltext
Appears in Collections:MSE Journal Articles

Citations 20

Updated on Mar 10, 2021

Citations 20

Updated on Mar 7, 2021

Page view(s)

Updated on Sep 17, 2021

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.